)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Vicore Pharma
Vicore Pharma (VICO) investor relations material
Vicore Pharma Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary8 Apr, 2026
Strategic vision and financial position
Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology.
Operates from Stockholm, Cambridge, and Copenhagen, with a $303M market cap and $127M in financial reserves as of early 2026.
Publicly listed on Nasdaq Stockholm and backed by leading US and European investors.
Lead program and clinical pipeline
Lead asset buloxibutid is a first-in-class oral AT2 receptor agonist for IPF, with Orphan Drug and Fast Track FDA designations.
Currently in a global Phase 2b trial (ASPIRE) targeting full enrollment by H1 2026.
Holds global rights except for Japan, where partnered with Nippon Shinyaku.
Market opportunity and unmet need
IPF is a fatal, progressive disease with high unmet need; current therapies offer only modest benefit and poor tolerability.
Global IPF market projected to grow from $4.2B in 2024 to over $10B by 2030-33, driven by new approvals and rising diagnosis rates.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vicore Pharma
- Phase II-B IPF trial nears enrollment completion, targeting best-in-class efficacy and safety.VICO
Leerink Global Healthcare Conference 20269 Mar 2026 - Buloxibutid shows robust efficacy and safety in IPF, with pivotal Phase 2b results expected by mid-2027.VICOTD Cowen 46th Annual Health Care Conference4 Mar 2026
- Expanded ASPIRE trial, raised SEK 455M, and maintained strong cash for ongoing IPF development.VICOQ4 202527 Feb 2026
- Buloxibutid shows strong potential in IPF, with pivotal phase IIb data expected by mid-2027.VICOOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
- SEK 782m rights issue, 80% committed, funds 270-patient IPF trial and pipeline growth.VICOInvestor Update21 Jan 2026
- Oral AT2 receptor agonist for IPF shows promising efficacy and safety in phase II-A study.VICO44th Annual J.P. Morgan Healthcare Conference15 Jan 2026
- Buloxibutid demonstrates strong efficacy and safety in IPF, targeting a multi-billion dollar market.VICOCompany presentation15 Jan 2026
- Buloxibutid demonstrated durable lung function gains in IPF, with a pivotal phase IIb trial ongoing.VICOStifel 2024 Healthcare Conference13 Jan 2026
- Promising IPF therapy shows strong efficacy in phase IIa, with pivotal phase IIb study ongoing.VICOCantor Global Healthcare Conference 20255 Jan 2026
Next Vicore Pharma earnings date
Q1 20266 May, 2026
Vicore Pharma
Next Vicore Pharma earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage